



PATENT

Case Docket No. AVANIR.124A

Date: October 22, 2004

11FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jagadish C. Sircar, et al.
Appl. No. : 10/821,667
Filed : April 9, 2004
For : IMIDAZOLE DERIVATIVES FOR
TREATMENT OF ALLERGIC AND
HYPERPROLIFERATIVE
DISORDERS
Examiner : Unknown
Group Art Unit : 1626

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 22, 2004

(Date)

Connie C. Tong

Connie C. Tong, Reg. No. 52,292

TRANSMITTAL LETTER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) PTO Form 1449 with two (2) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Connie C. Tong

Connie C. Tong
Registration No. 52,292
Agent of Record
Customer No. 20,995
(949) 760-0404

**INFORMATION DISCLOSURE STATEMENT**

: Jagadish C. Sircar, et al.
App. No. : 10/821,667
Filed : April 9, 2004
For : IMIDAZOLE DERIVATIVES FOR
TREATMENT OF ALLERGIC AND
HYPERPROLIFERATIVE DISORDERS
Examiner : Unknown
Group Art Unit : 1626

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing two (2) references that are also enclosed.

This Information Disclosure Statement is being filed before the mailing date of a final action under 37 C.F.R. § 1.113 and before the mailing date of a Notice of Allowance under § 1.311. A certification under 37 C.F.R. § 1.97(e) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).


CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this Information Disclosure Statement.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: October 22, 2004

By: 

Connie C. Tong
Registration No. 52,292
Agent of Record
Customer No. 20,995
(949) 760-0404

 <p>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	ATTY. DOCKET NO. AVANIR.124A	APPLICATION NO. 10/821,667
	APPLICANT Jagadish C. Sircar, et al.	
	FILING DATE April 9, 2004	GROUP 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1	WO 01/72737 A1	10/4/01	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	2	Timothy F. Gallagher, et al., "2,4,5-Triarylimidazole Inhibitors of IL-1 Biosynthesis," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 5, No. 11, pp. 1171-1176, 1995

H:\DOCS\CCT\CCT-6681.DOC:Cb 102204

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	